



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
08/887,505	07/02/1997	ROBERT L. KILKUSKIE	HYZ-040CIP	HYZ-040CIP 1117	
7	590 07/01/2004		EXAMINER		
HALE AND DORR			JOHANNSEN, DIANA B		
60 STATE STREET BOSTON, MA 02109			ART UNIT	PAPER NUMBER	
			1634	1634 DATE MAILED: 07/01/2004	
		•	DATE MAILED: 07/01/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

8
℅
Ψ

	Application No.	Applicant(s)	
	08/887,505	KILKUSKIE ET AL.	
Office Action Summary	Examiner	Art Unit	_
	Diana B. Johannsen	1634	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be timed within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 01 M	<u>arch 2004</u> .		
	action is non-final.		
3) Since this application is in condition for allowar			
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.	
Disposition of Claims			
4)⊠ Claim(s) <u>1-46</u> is/are pending in the application.			
4a) Of the above claim(s) is/are withdraw			
5) Claim(s) is/are allowed.			
6)☐ Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) 1-46 are subject to restriction and/or	election requirement.		
Application Papers			
9) The specification is objected to by the Examine	r. ´		
10) The drawing(s) filed on is/are: a) acc		Examiner.	
Applicant may not request that any objection to the			
Replacement drawing sheet(s) including the correct			
11) The oath or declaration is objected to by the Ex			
Out out to some day 25 H C C S 440			
Priority under 35 U.S.C. § 119		\	
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document	s have been received.		
2. Certified copies of the priority document			
<ol> <li>Copies of the certified copies of the prio application from the International Bureau</li> </ol>		eu III IIIIS Ivalional Slage	
* See the attached detailed Office action for a list		ed.	
occurre attached detailed embe determine a wet	<b>6</b>		
Attachment(s)			
Notice of References Cited (PTO-892)	4) Interview Summary		
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> </ul>	Paper No(s)/Mail D  5) Notice of Informal F	ate Patent Application (PTO-152)	
Paper No(s)/Mail Date	6)  Other:	· · · · · · · · · · · · · · · · · · ·	

Application/Control Number: 08/887,505

Art Unit: 1634

## **ELECTION/RESTRICTION**

- 1. It is noted that the paper and computer readable forms of the Sequence Listing filed on March 1, 2004 have been entered.
- 2. This application contains claims directed to the following patentably distinct species of the claimed invention:
  - a) The numerous synthetic oligonucleotide sequences disclosed as being complementary to contiguous portions of the 5' UTR of hepatitis C virus, as set forth in claim 1 (see also claims 21, 29, and 31);
  - b) The numerous synthetic oligonucleotide sequences disclosed as being complementary to non-contiguous regions of "an HCV messenger or genomic RNA" (see claim 2, as well as dependent claims 7, 22-24, 26, 29, and 31, which recite SEQ ID Nos corresponding to particular species).
- 3. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from each of a) and b) above for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claim is generic. Specifically, one SEQ ID NO of a) and one SEQ ID NO of b) should be elected. It is noted that the sequence of independent claim 46 (SEQ ID NO: 117) will also be searched, and that claim examined. The large number of individual sequences encompassed by the claims necessitates this requirement, as the claims as now written cannot be searched and examined without posing a serious burden.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and

Application/Control Number: 08/887,505

Art Unit: 1634

a listing of all claims readable thereon, including any claims subsequently added.

An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 08/887,505

Art Unit: 1634

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Diana B. Johannsen whose telephone number is 571/272-0744. The examiner can normally be reached on Monday-Friday, 7:30 am-4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones can be reached at 571/272-0745. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Diana B. Johannsen

**Primary Examiner** 

June 28, 2004